Literature DB >> 2582769

Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost).

M W Rodger1, D T Baird.   

Abstract

The pattern and amount of blood loss following induction of therapeutic abortion using mifepristone (RU 486) and a prostaglandin E analogue (gemeprost) was studied in 222 women of less than 63 days amenorrhoea. A single oral dose of mifepristone (400, 500 or 600 mg) was followed 48 hours later by a half or 1 mg gemeprost vaginal pessary. Complete abortion occurred in 218 (98%) women without necessity for surgical evacuation of the uterus. Bleeding commonly occurred following administration of mifepristone and prior to prostaglandin administration. The median duration of bleeding following abortion was 13 days with a range of from 1 to 44 days. There was a wide individual variation in measured blood loss between women, from 14 to 512 ml, with a median loss of 74 ml. The amount of blood loss was independent of the dose of mifepristone or prostaglandin but was significantly correlated with gestation. These results confirm that the combination of mifepristone and gemeprost is a highly effective and safe method of inducing therapeutic abortion medically. As the amount of blood loss increases with increasing gestation, it is suggested that its use should be restricted to women with amenorrhoea less than or equal to 56 days.

Entities:  

Keywords:  Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Amenorrhea; Biology; Bleeding; Clinical Research; Demographic Factors; Diseases; Endocrine System; Evaluation; Family Planning; Fertility Control, Postconception; Hormone Antagonists; Hormones; Menstruation Disorders; Physiology; Population; Population Dynamics; Research Methodology; Ru-486; Signs And Symptoms; Time Factors

Mesh:

Substances:

Year:  1989        PMID: 2582769     DOI: 10.1016/0010-7824(89)90051-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

Review 1.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 2.  Medical termination of pregnancy.

Authors:  J Guillebaud
Journal:  BMJ       Date:  1990 Aug 18-25

3.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 4.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 5.  The search for meaning: RU 486 and the law of abortion.

Authors:  S S Banwell; J M Paxman
Journal:  Am J Public Health       Date:  1992-10       Impact factor: 9.308

6.  Assessment of anaemia and nutritional status of antenatal women attending a tertiary care hospital.

Authors:  Kanupriya Arora; Anupama Bahadur; Divya Mishra; Rajlaxmi Mundhra
Journal:  J Family Med Prim Care       Date:  2022-06-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.